Farther Finance Advisors, LLC
Position in ACTU — Actuate Therapeutics, Inc.
CIK 1992825
SAN FRANCISCO, CA
Position in ACTU
as of Mar 31, 2026
· filed Apr 7, 2026
Position Value
$19
New position
Shares Held
7
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Farther Finance Advisors, LLC holds $14,679,899 across 278 Biotechnology names. ACTU ranks #263 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
4,752 | $2,121,958 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,870 | $1,444,836 | |
| 3 | MRNA |
Moderna, Inc.
|
20,211 | $1,026,718 | |
| 4 | SMMT |
Summit Therapeutics Inc.
|
50,316 | $953,991 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
|
13,333 | $861,711 | |
| 6 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
11,971 | $750,581 | |
| 7 | EXEL |
Exelixis, Inc.
|
16,443 | $705,240 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
7,857 | $443,841 |
All Filings in ACTU
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $19 | 7 | Shares | Sole | 2026-04-07 | |
| No filing history on record for this holder in this stock. | ||||||